2023-08-31 08:29:27 ET
More on Acer, Zevra, etc.
- Zevra Therapeutics, Inc. ( ZVRA ) Q2 2023 Earnings Call Transcript
- Acer Therapeutics will reacquire OLPRUVA rights from Relief Therapeutics
- Zevra seeks FDA nod to start trial of KP1077 for sleep disorder narcolepsy
- Acer Therapeutics GAAP EPS of -$0.54 misses by $0.17
- Acer Therapeutics stock dips on $2.7M securities offering
- Acer stock slumps ~45% as ACER-801 paused after hot flashes trial disappoints; cash woes
- Zevra to get US patent linked to sleep disorder therapy
- Zevra Therapeutics GAAP EPS of -$0.26 misses by $0.08, revenue of $2.3M misses by $0.8M
- Acer Therapeutics rises on starting trial of ACER-801 in men with adenocarcinoma of the prostate
For further details see:
Acer Therapeutics surges as Zevra agrees to acquire for up to $91M